Efficacy of Selpercatinib in RET Fusion-Positive Thyroid Cancers
Vivek Subbiah, MD, discusses the updated results of the LIBRETTO-001 trial, specifically the effect of selpercatinib on RET fusion-positive thyroid tumors.
Vivek Subbiah, MD, a medical oncologist at the University of Texas MD Anderson Cancer Center, discusses the updated results of the LIBRETTO-001 trial (NCT03157128), specifically the effect of selpercatinib (Retevmo) on RET fusion-positive thyroid tumors.
According to Subbiah, of the 55 initial patients who were previously treated with a multikinase inhibitor, the response rate was 69% and the 1-year progression-free survival (PFS) rate was 82%. In 88 patients who were never treated with a multikinase inhibitor, the response rate was 73% and the 1-year PFS rate was 92%. In the 19 patients who were treatment naïve, the response rate was 79% and the 1-year PFS rate was 64%.
Updated results showed that the overall response rate was 79% in patients with previously treated RET fusion-positive thyroid cancer. In the treatment-naïve group, the response rate was 100%, according to Subbiah. Of those responses, 71% were ongoing and 64% remained progression-free. These data supported the approval of selpercatinib capsules for the treatment of thyroid cancer harboring RET alterations.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
No Improvement With Durvalumab vs Cetuximab in Advanced HNSCC
January 9th 2025The NRG-HN004 trial showed that durvalumab did not improve outcomes vs cetuximab in locoregionally advanced head and neck squamous cell carcinoma undergoing radiotherapy with contraindications to cisplatin, leading to early trial closure.
Read More
